Treatment fractionation for stereotactic radiotherapy of lung tumours: A modelling study of the influence of chronic and acute hypoxia on tumour control probability

Radiation Oncology

Volumn 9, Issue 1, 2014, Pages

  Lindblom, Emely ^a   Antonovic, Laura ^a   Dasu, Alexandru ^b   Lax, Ingmar ^c   Wersäll, Peter ^c   Toma Dasu, Iuliana ^a,d  

^a STOCKHOLM UNIVERSITY   (Sweden)

^b LINKÖPING UNIVERSITY   (Sweden)

^c KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^d KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Hypofractionation; Hypoxia; NSCLC; SBRT

Indexed keywords

ARTICLE; CANCER RADIOTHERAPY; CANCER SURVIVAL; CELL HYPOXIA; CONTROLLED STUDY; HUMAN; LUNG NON SMALL CELL CANCER; NONHUMAN; OVERALL SURVIVAL; OXYGEN ENHANCEMENT RATIO; OXYGEN TENSION; RADIATION DOSE; RADIATION DOSE DISTRIBUTION; RADIATION DOSE FRACTIONATION; RADIATION RESPONSE; RADIOLOGICAL PARAMETERS; RADIOSENSITIVITY; REOXYGENATION; STEREOTACTIC BODY RADIATION THERAPY; THREE DIMENSIONAL IMAGING; TREATMENT OUTCOME; TUMOR CONTROL PROBABILITY; ACUTE DISEASE; ANOXIA; CARCINOMA, NON-SMALL-CELL LUNG; CELL SURVIVAL; CHRONIC DISEASE; COMPUTER SIMULATION; LUNG NEOPLASMS; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; RADIOSURGERY; STATISTICAL MODEL;

OXYGEN;

ACUTE DISEASE; ANOXIA; CARCINOMA, NON-SMALL-CELL LUNG; CELL SURVIVAL; CHRONIC DISEASE; COMPUTER SIMULATION; DOSE FRACTIONATION; HUMANS; LUNG NEOPLASMS; MODELS, STATISTICAL; OXYGEN; RADIOSURGERY;

EID: 84903339294     PISSN: None     EISSN: 1748717X     Source Type: Journal    
DOI: 10.1186/1748-717X-9-149     Document Type: Article

References (36)

1. Lax I, Blomgren H, Näslund I, Svanström R. Stereotactic radiotherapy ofmalignancies in the abdomen. Acta Oncol 1994, 33:677-683. 10.3109/02841869409121782, 7946448.
2. Blomgren H, Lax I, Näslund I, Svanström R. Stereotactic high dose fraction radiation therapy of extracranial tumours using an accelerator. Acta Oncol 1995, 34:861-870. 10.3109/02841869509127197, 7576756.
3. Hof H, Muenter M, Oetzel D, Hoess A, Debus J, Herfarth K. Stereotactic single-dose radiotherapy (radiosurgery) of early-stage nonsmall-cell lung cancer (NSCLC). Cancer 2007, 110:148-155. 10.1002/cncr.22763, 17516437.
4. Fritz P, Kraus HJ, Blaschke T, Mühlnickel W, Strauch K, Engel-Riedel W, Chemaissani A, Stoelben E. Stereotactic, high single-dose irradiation of stage I non-small cell lung cancer (NSCLC) using four-dimensional CT scans for treatment planning. Lung Cancer 2008, 60:193-199. 10.1016/j.lungcan.2007.10.005, 18045732.
5. Zimmermann FB, Geinitz H, Schill S, Grosu A, Schratzenstaller U, Molls M, Jeremic B. Stereotactic hypofractionated radiation therapy for stage I non-small cell lung cancer. Lung Cancer 2005, 48:107-114. 10.1016/j.lungcan.2004.10.015, 15777977.
6. Baumann P, Nyman J, Hoyer M, Wennberg B, Gagliardi G, Lax I, Drugge N, Ekberg L, Friesland S, Johansson KA, Lund J, Morhed E, Nilsson K, Levin N, Paludan M, Sederholm C, Traberg A, Wittgren L, Lewensohn R. Outcome in a prospective phase II trial of medically inoperable stage I non-small-cell lung cancer patients treated with stereotactic body radiotherapy. J Clin Oncol 2009, 27:3290-3296. 10.1200/JCO.2008.21.5681, 19414667.
7. Olsen JR, Robinson CG, El Naqa I, Creach KM, Drzymala RE, Bloch C, Parikh PJ, Bradley JD. Dose-response for stereotactic body radiotherapy in early-stage non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2011, 81:e299-e303. 10.1016/j.ijrobp.2011.01.038, 21477948.
8. Haasbeek CJA, Lagerwaard FJ, Antonisse ME, Slotman BJ, Senan S. Stage I nonsmall cell lung cancer in patients aged ≥ 75 years: outcomes after stereotactic radiotherapy. Cancer 2010, 116:406-414. 10.1002/cncr.24759, 19950125.
9. Takeda A, Sanuki N, Kunieda E, Ohashi T, Oku Y, Takeda T, Shigematsu N, Kubo A. Stereotactic body radiotherapy for primary lung cancer at a dose of 50 Gy total in five fractions to the periphery of the planning target volume calculated using a superposition algorithm. Int J Radiat Oncol Biol Phys 2009, 73:442-448. 10.1016/j.ijrobp.2008.04.043, 18990507.
10. Song CW, Park H, Griffin RJ, Levitt SH. Radiobiology of stereotactic radiosurgery and stereotactic body radiation therapy. Technical Basis of Radiation Therapy - Practical Clinical Applications 2012, 51-61. Berlin, Heidelberg: Springer-Verlag, Levitt SH, Purdy JA, Perez CA, Poortmans P, 5.
11. Withers HR, Taylor JMG, Maciejewski B. The hazard of accelerated tumour clonogen repopulation during radiotherapy. Acta Oncol 1988, 27:131-146. 10.3109/02841868809090333, 3390344.
12. Paganetti H. Changes in tumour cell response due to prolonged dose delivery times in fractionated radiation therapy. Int J Radiat Oncol Biol Phys 2005, 63:892-900. 10.1016/j.ijrobp.2005.07.953, 16199319.
13. Hall EJ, Giaccia AJ. Radiobiology for the Radiologist 2006, 85-89-378-379. Philadelphia: Lippincott/ Williams & Wilkins, 6.
14. Kallman RF. The phenomenon of reoxygenation and its implications for fractionated radiotherapy. Radiology 1972, 105:135-142. 10.1148/105.1.135, 4506641.
15. Brown JM. Evidence for acutely hypoxic cells in mouse tumours, and a possible mechanism of reoxyenation. Br J Radiol 1979, 52:650-656. 10.1259/0007-1285-52-620-650, 486895.
16. Ljungkvist AS, Bussink J, Kaanders JH, Wiedenmann NE, Vlasman R, van der Kogel AJ. Dynamics of hypoxia, proliferation and apoptosis after irradiation in a murine tumour model. Rad Res 2006, 165:326-336.
17. Ruggieri R, Naccarato S, Nahum AE. Severe hypofractionation: non-homogeneous tumour dose delivery can counteract tumour hypoxia. Acta Oncol 2010, 49:1304-1314. 10.3109/0284186X.2010.486796, 20500031.
18. Carlson DJ, Keall PJ, Loo BW, Chen ZJ, Brown JM. Hypofractionation results in reduced tumour cell kill compared to conventional fractionation for tumours with regions of hypoxia. Int J Radiat Oncol Biol Phys 2011, 79:1188-1195. 10.1016/j.ijrobp.2010.10.007, 3053128, 21183291.
19. Dasu A, Toma-Dasu I, Karlsson M. Theoretical simulation of tumour oxygenation and results from acute and chronic hypoxia. Phys Med Biol 2003, 48:2829-2842. 10.1088/0031-9155/48/17/307, 14516104.
20. Dasu A, Toma-Dasu I, Karlsson M. The effects of hypoxia on the theoretical modelling of tumour control probability. Acta Oncol 2005, 44:563-571. 10.1080/02841860500244435, 16165915.
21. Toma-Dasu I, Dasu A, Brahme A. Dose prescription and optimisation based on tumour hypoxia. Acta Oncol 2009, 48:1181-1192. 10.3109/02841860903188643, 19863227.
22. Barendsen GW. Dose fractionation, dose rate and iso-effect relationships for normal tissue responses. Int J Radiat Oncol Biol Phys 1982, 8:1981-1997. 10.1016/0360-3016(82)90459-X, 6759484.
23. Park C, Papiez L, Zhang S, Story M, Timmerman RD. Universal survival curve and single fraction equivalent dose: useful tools in understanding potency of ablative radiotherapy. Int J Radiat Oncol Biol Phys 2008, 70:847-852. 10.1016/j.ijrobp.2007.10.059, 18262098.
24. Kirkpatrick JP, Brenner DJ, Orton CG. Point/Counterpoint. The linear-quadratic model is inappropriate to model high dose per fraction effects in radiosurgery. Med Phys 2009, 36:3381-3384. 10.1118/1.3157095, 19746770.
25. Alper T. Cellular radiobiology 1979, Cambridge, UK: Cambridge University Press.
26. Toma-Dasu I, Dasu A. Modelling tumour oxygenation, reoxygenation and implications on treatment outcome. Comput Math Methods Med 2013, 2013:141087. 3557613, 23401721.
27. Konerding MA, Malkusch W, Klapthor B. Evidence for characteristic vascular patterns in solid tumours: quantitative studies using corrosion casts. Br J Cancer 1999, 80:724-732. 10.1038/sj.bjc.6690416, 2362271, 10360650.
28. Antonovic L, Lindblom E, Dasu A, Bassler N, Furusawa Y, Toma-Dasu I. Clinical oxygen enhancement ratio of tumors in carbon ion radiotherapy: The influence of local oxygenation changes. J Radiat Res 2014, Epub ahead of print, doi:10.1093/jrr/rru020.
29. Dasu A, Toma-Dasu I. Prostate alpha/beta revisited - an analysis of clinical results from 14 168 patients. Acta Oncol 2012, 51:963-974. 10.3109/0284186X.2012.719635, 22966812.
30. Dale RG. The application of the linear-quadratic dose-effect equation to fractionated and protracted radiotherapy. Br J Radiol 1985, 58:515-528. 10.1259/0007-1285-58-690-515, 4063711.
31. Wennberg B, Lax I. The impact of fractionation in SBRT: analysis with the linear quadratic model and the universal survival curve model. Acta Oncol 2013, 52:902-909. 10.3109/0284186X.2012.728292, 23327339.
32. Overgaard J. Hypoxic radiosensitization: adored and ignored. J Clin Oncol 2007, 25:4066-4074. 10.1200/JCO.2007.12.7878, 17827455.
33. Rasey JS, Koh WJ, Evans ML, Peterson LM, Lewellen TK, Graham MM, Krohn KA. Quantifying regional hypoxia in human tumors with positron emission tomography of [18 F]Fluoromisonidazole: a pretherapy study of 37 patients. Int J Radiat Oncol Biol Phys 1996, 36:417-428. 10.1016/S0360-3016(96)00325-2, 8892467.
34. Park HJ, Griffin RJ, Hui S, Levitt SH, Song CW. Radiation-induced vascular damage in tumors: implications of vascular damage in ablative hypofractionated radiotherapy (SBRT and SRS). Rad Res 2012, 177:311-327.
35. Yang J, Fowler JF, Lamond JP, Lanciano R, Feng J, Brady LW. Red shell: defining a high-risk zone of normal tissue damage in stereotactic body radiation therapy. Int J Radiat Oncol Biol Phys 2010, 77:903-909. 10.1016/j.ijrobp.2009.12.069, 20400240.
36. Tomé WA. Universal survival curve and single fraction equivalent dose: useful tools in understanding potency of ablative radiotherapy: in regard to Parks et al. (Int J Radiat Oncol Biol Phys 2008;72:1620-1621). Int J Radiat Oncol Biol Phys 2009, 73:1286.